Bi Asset Management Fondsmaeglerselskab A Gilead Sciences, Inc. Transaction History

Bi Asset Management Fondsmaeglerselskab A

$9.48 Billion
Q4 2024

A detailed history of Bi Asset Management Fondsmaeglerselskab A transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Bi Asset Management Fondsmaeglerselskab A holds 466,506 shares of GILD stock, worth $51.3 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares

466,506

Previous 147,008 217.33%

Holding current value

$51.3 Million

Previous $12.3 Million 249.62%

% of portfolio

0.45%

Previous 0.21%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$83.95 - $97.9 $26.8 Million - $31.3 Million	319,498 Added 217.33%	466,506 $43.1 Million
Q3 2024 Nov 13, 2024	BUY	$66.59 - $83.99 $2.11 Million - $2.66 Million	31,652 Added 27.44%	147,008 $12.3 Million
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $35 Million - $40.4 Million	-553,846 Reduced 82.76%	115,356 $7.92 Million
Q1 2024 May 03, 2024	BUY	$71.58 - $87.29 $1.43 Million - $1.74 Million	19,969 Added 3.08%	669,202 $49 Million
Q4 2023 Feb 09, 2024	BUY	$73.27 - $83.09 $3.14 Million - $3.56 Million	42,826 Added 7.06%	649,233 $52.6 Million
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $1.16 Million - $1.27 Million	-15,689 Reduced 2.52%	606,407 $45.4 Million
Q2 2023 Aug 03, 2023	BUY	$76.01 - $86.7 $9.85 Million - $11.2 Million	129,535 Added 26.3%	622,096 $47.9 Million
Q1 2023 May 12, 2023	SELL	$77.31 - $88.08 $556,090 - $633,559	-7,193 Reduced 1.44%	492,561 $40.9 Million
Q4 2022 Feb 13, 2023	BUY	$62.32 - $89.47 $25.2 Million - $36.1 Million	404,031 Added 422.08%	499,754 $42.9 Million
Q3 2022 Nov 07, 2022	SELL	$59.54 - $68.01 $2.78 Million - $3.18 Million	-46,770 Reduced 32.82%	95,723 $5.91 Million
Q2 2022 Aug 12, 2022	SELL	$57.72 - $65.01 $4.72 Million - $5.31 Million	-81,728 Reduced 36.45%	142,493 $8.81 Million
Q1 2022 May 11, 2022	BUY	$57.92 - $72.58 $202,430 - $253,667	3,495 Added 1.58%	224,221 $13.3 Million
Q4 2021 Feb 02, 2022	SELL	$64.88 - $73.64 $1.35 Million - $1.54 Million	-20,866 Reduced 8.64%	220,726 $16 Million
Q3 2021 Nov 09, 2021	BUY	$67.69 - $73.03 $6.99 Million - $7.54 Million	103,267 Added 74.66%	241,592 $16.9 Million
Q2 2021 Aug 06, 2021	SELL	$63.47 - $69.35 $939,482 - $1.03 Million	-14,802 Reduced 9.67%	138,325 $9.53 Million
Q1 2021 May 10, 2021	BUY	$60.0 - $68.46 $440,220 - $502,291	7,337 Added 5.03%	153,127 $9.9 Million
Q4 2020 Feb 12, 2021	BUY	$56.65 - $64.55 $2.49 Million - $2.84 Million	43,953 Added 43.16%	145,790 $8.49 Million
Q3 2020 Nov 09, 2020	BUY	$62.1 - $78.08 $733,214 - $921,890	11,807 Added 13.11%	101,837 $6.44 Million
Q2 2020 Aug 05, 2020	SELL	$72.34 - $84.0 $8.01 Million - $9.3 Million	-110,741 Reduced 55.16%	90,030 $6.93 Million
Q1 2020 May 11, 2020	SELL	$62.63 - $80.22 $6.03 Million - $7.73 Million	-96,311 Reduced 32.42%	200,771 $15 Million
Q4 2019 Mar 19, 2020	SELL	$61.62 - $67.78 $13.8 Million - $15.2 Million	-224,152 Reduced 43.0%	297,082 $19.3 Million
Q3 2019 Mar 19, 2020	SELL	$62.51 - $69.0 $15.9 Million - $17.6 Million	-254,609 Reduced 32.82%	521,234 $33 Million
Q2 2019 Mar 19, 2020	BUY	$61.87 - $69.38 $16.3 Million - $18.3 Million	263,581 Added 51.45%	775,843 $52.4 Million
Q1 2019 Mar 19, 2020	BUY	$62.53 - $70.05 $14.9 Million - $16.6 Million	237,512 Added 86.45%	512,262 $33.3 Million
Q4 2018 Mar 19, 2020	SELL	$60.54 - $79.0 $2.48 Million - $3.23 Million	-40,900 Reduced 12.96%	274,750 $17.2 Million
Q3 2018 Mar 19, 2020	BUY	$71.28 - $78.92 $21.7 Million - $24 Million	304,350 Added 2693.36%	315,650 $24.4 Million
Q2 2018 Mar 19, 2020	BUY	$64.88 - $75.68 $733,144 - $855,184	11,300 New	11,300 $800,000

Others Institutions Holding GILD

# of Institutions

2,090

Shares Held

1.02B

Call Options Held

8.73M

Put Options Held

9.63M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $138B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bi Asset Management Fondsmaeglerselskab A, based on Form 13F filings with the SEC.

News

Stay updated on Bi Asset Management Fondsmaeglerselskab A with notifications on news.

Account

Bi Asset Management Fondsmaeglerselskab A Gilead Sciences, Inc. Transaction History